Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Late-Breaking Abstract! Alphamab Oncology Presented the Latest Clinical Data of Anti-HER2 bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024

JSKN033 presented a favorable safety profile and encouraging anti-cancer activity in heavily treated patients
IND Application for a Phase Ⅲ Clinical Study of KN026 Combined with Albumin-bound Docetaxel as Neoadjuvant Treatment for Breast Cancer was Approved

as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer
Alphamab Oncology and CSPC Achieved a Licensing Agreement on Anti-HER2 Bispecific ADC JSKN003 in Mainland China

the Company is entitled to receive upfront payment and milestone payments of up to RMB 3.08 billion in total, and is also entitled to receive a double-digit percentage of royalties on net product sales of JSKN003

VISION, MISSION AND CORE VALUES

Our Mission : To make cancer manageable and curable

Our Vision : To develop differentiated, clinically valuable and globally competitive new drugs

Our Core Values : Innovation, Ownership, Integrity, Quality, Growth

Learn More

Proprietary Platforms
Innovative Pipeline
Biologics Manufacturing

WORLD-CLASS BISPECIFIC, ADC AND MIX-MAB PLATFORMS

In complex diseases, such as cancer and viral infection, multiple signaling pathways or mechanisms are involved. Alphamab Oncology has developed several proprietary technical approaches to provide innovative solutions to address this growing trend in the development of modern biotherapeutics.

Learn More

INNOVATIVE PIPELINE WITH SIGNIFICANT POTENTIAL AND MITIGATED DEVELOPMENT RISK

Leveraging its proprietary technology platforms, Alphamab Oncology has developed an exciting pipeline with clear differentiation and global competitiveness.

Learn More

STATE OF ART cGMP MANUFACTURING WITH A SOLID TRACK RECORD

The production of biologics, such as antibody drugs, is a complex, lengthy and costly process. We have established our own cGMP production facilities with strong in house expertise to address the manufacturing issues.

Learn More